On October 20, 2023, Beijing Youngen Technology Co., Ltd., a subsidiary of Beijing Hotgen Biotechnology Co., Ltd., announced a strategic cooperation with Shanghai Genoval Biopharmaceutical Technology Co., Ltd. to jointly develop multiple "first in class" small nucleic acid drugs targeting the liver and extrahepatic tissues, covering various diseases.
Dr. Gao Qi, CEO of Beijing Youngen Technology Co., Ltd., stated that Youngen is one of the professional medical biotechnology companies dedicated to the research and development of small nucleic acid drugs in the field of gene therapy.
The company adheres to independent innovation and has established multiple core technology platforms, including a new target discovery platform, a high-throughput efficacy evaluation platform, a bioinformatics and artificial intelligence development platform, around metabolic and cardiovascular system diseases. It has also laid out a series of innovative nucleic acid drug pipelines. Among them, based on the company's independent intellectual property rights, breakthrough progress has been made in the development of small nucleic acid innovative drugs for reducing blood lipids, lowering blood sugar, and reducing body weight.
Dr. Li Chong, CEO of Shanghai Genoval Biopharmaceutical Technology Co., Ltd., stated that Genoval is a company dedicated to developing innovative drugs for targeted delivery of small nucleic acids. Since its establishment, we have always adhered to the belief of "having lofty aspirations and being down-to-earth", and have made every research solid and thorough. At present, the company has 5 core technology platforms and has submitted multiple international patents for its core products through the PCT pathway.
This strategic cooperation fully integrates Youngen's outstanding target discovery and development capabilities, as well as Genoval 's unique nucleic acid chemical synthesis and targeted delivery technology. Through joint development plans and commercialization methods, both parties anchor the full cycle management of small nucleic acid drug research and development, striving to establish an internationally leading small nucleic acid drug incubation and transformation platform. With the relevant advantages of Genoval, Youngen will accelerate the development process of multiple international "first in class" small nucleic acid drugs, providing health protection for the increasingly aging population!
